Targeting immunosuppression by Tregs with monoclonal antibodies against GARP.

Lienart, Stéphanie;Stockis, Julie;Dedobbeleer, Olivier;Lucas, Sophie
(2016) OncoImmunology — Vol. 5, n° 3, p. e1074379 (2016)

Files

document.pdf
  • Restricted Access
  • Adobe PDF
  • 187.12 KB
Request a copy

Details

Authors
Abstract
Reducing Treg function in cancer patients should augment antitumor immune responses. We recently uncovered a mechanism of immunosuppression by human Tregs that implies transmembrane protein GARP and production of active TGF-ß1. We obtained monoclonal antibodies that block this process and could thus serve as a novel approach for cancer immunotherapy.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Lienart, S., Stockis, J., Dedobbeleer, O., & Lucas, S. (2016). Targeting immunosuppression by Tregs with monoclonal antibodies against GARP. OncoImmunology, 5(3), e1074379. https://doi.org/10.1080/2162402X.2015.1074379 (Original work published 2016)